In a group sequential clinical trial, accumulated data are analyzed at numerous time points to allow early decisions about a hypothesis of interest. These designs have historically been recommended for their ethical, administrative, and economic benefits. In this article, we first discuss a collection of new commands for computing the stopping boundaries and required group size of various classical group sequential designs, assuming a normally distributed outcome variable. Then, we demonstrate how the performance of several designs can be compared graphically.
ArmitageP.1975. Sequential Medical Trials. 2nd ed. Oxford: Blackwell.
2.
BarthelF. M.-S., RoystonP., and ParmarM. K. B.2009. A menu-driven facility for sample-size calculation in novel multiarm, multistage randomized controlled trials with a time-to-event outcome. Stata Journal9: 505–523.
3.
BrattonD.2014. nstagebin: Stata module to perform sample size calculation for multi-arm multi-stage randomised controlled trials with binary outcomes. Statistical Software Components S457911, Department of Economics, Boston College. https://ideas.repec.org/c/boc/bocode/s457911.html.
4.
BrattonD. J., Choodari-OskooeiB., and RoystonP.2015. A menu-driven facility for sample-size calculation in multiarm, multistage randomized controlled trials with time-to-event outcomes: Update. Stata Journal15: 350–368.
5.
BrentR. P.1973. An algorithm with guaranteed convergence for finding a zero of a function. In Algorithms for Minimization without Derivatives, chap. 4. Englewood Cliffs, NJ: Prentice Hall.
6.
Gordon LanK. K., and DemetsD. L.1983. Discrete sequential boundaries for clinical trials. Biometrika70: 659–663.
7.
GraylingM. J., and ManderA. P. Forthcoming. Calculations involving the multivariate normal and multivariate t distributions. Stata Journal.
8.
HaybittleJ. L.1971. Repeated assessment of results in clinical trials of cancer treatment. British Journal of Radiology44: 793–797.
9.
HooperR.2013. Versatile sample-size calculation using simulation. Stata Journal13: 21–38.
10.
JennisonC., and TurnbullB. W.2000. Group Sequential Methods with Applications to Clinical Trials.Boca Raton, FL: Chapman & Hall/CRC.
11.
O'BrienP. C., and FlemingT. R.1979. A multiple testing procedure for clinical trials. Biometrics35: 549–556.
12.
PampallonaS., and TsiatisA. A.1994. Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis. Journal of Statistical Planning and Inference42: 19–35.
13.
PetoR., PikeM. C., ArmitageP., BreslowN. E., CoxD. R., HowardS. V., MantelN., McPhersonK., PetoJ., and SmithP. G.1976. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. British Journal of Cancer34: 585–612.
14.
PocockS. J.1977. Group sequential methods in the design and analysis of clinical trials. Biometrika64: 191–199.
15.
WaldA.1947. Sequential Analysis.New York: Wiley.
16.
WangS. K., and TsiatisA. A.1987. Approximately optimal one-parameter boundaries for group sequential trials. Biometrics43: 193–199.
17.
WasonJ.2015a. Multi-arm multi-stage designs for clinical trials with treatment selection. In Modern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects, ed. SverdlovO., 389–410. Boca Raton, FL: Chapman & Hall/CRC.
18.
WasonJ. M. S.2015b. OptGS: An R package for finding near-optimal group-sequential designs. Journal of Statistical Software66(2): 1–13.
19.
WasonJ. M. S., and JakiT.2012. Optimal design of multi-arm multi-stage trials. Statistics in Medicine31: 4269–4279.
20.
WasonJ. M. S., ManderA. P., and ThompsonS. G.2012. Optimal multistage designs for randomised clinical trials with continuous outcomes. Statistics in Medicine31: 301–312.
21.
WhiteheadJ.1997. The Design and Analysis of Sequential Clinical Trials. Rev. 2nd ed. Chichester, UK: Wiley.
22.
WhiteheadJ., and StrattonI.1983. Group sequential clinical trials with triangular continuation regions. Biometrics39: 227–236.
23.
WhiteheadJ., Valdés-MárquezE., and LissmatsA.2009. A simple two-stage design for quantitative responses with application to a study in diabetic neuropathic pain. Pharmaceutical Statistics8: 125–135.
